Why Is Tesla Stock Falling?
Tesla stock reached an all-time high of $479.86 on December…
Sell
24
FULC Quote, Financials, Valuation and Earnings
Last price:
$3.69
Seasonality move
:
-28.47%
Day range:
$3.63 - $3.94
52-week range:
$2.86 - $13.70
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
0.77x
Volume:
848.4K
Avg. volume:
483.4K
1-year change:
-59.41%
Market cap:
$199M
Revenue:
$2.8M
EPS (TTM):
-$0.31
Analysts' Opinion
-
Consensus RatingFulcrum Therapeutics has received a consensus rating of Hold. The company's average rating is a Hold based on 1 Buy rating, 4 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $5.67, Fulcrum Therapeutics has an estimated upside of 53.57% from its current price of $3.69.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $2.00 representing 100% downside risk from its current price of $3.69.
Fair Value
-
According to the consensus of 5 analysts, Fulcrum Therapeutics has 53.57% upside to fair value with a price target of $5.67 per share.
FULC vs. S&P 500
-
Over the past 5 trading days, Fulcrum Therapeutics has underperformed the S&P 500 by -1.45% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Fulcrum Therapeutics does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Fulcrum Therapeutics has grown year-over-year revenues for 1 quarter straight. In the most recent quarter Fulcrum Therapeutics reported revenues of $80M.
Earnings Growth
-
Fulcrum Therapeutics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Fulcrum Therapeutics reported earnings per share of -$0.35.
Enterprise value:
-58.2M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
6.66x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-7.42%
Net Income Margin (TTM):
--
Return On Equity:
-8.07%
Return On Invested Capital:
-8.07%
Operating Margin:
65.62%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $10.7M | $2.6M | -- | $759K | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$107.7M | -$110.7M | -$28.4M | -$27.4M | -$23.1M | |
| EBITDA | -$105.2M | -$108.4M | -$26.7M | -$26.9M | -$22.7M | |
| Diluted EPS | -$2.56 | -$1.68 | -$0.31 | -$0.39 | -$0.35 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $132.1M | $246.2M | $227.7M | $262.5M | $267.5M | |
| Total Assets | $142.2M | $255.5M | $247.8M | $278.9M | $279M | |
| Current Liabilities | $26.5M | $20.6M | $14.7M | $14.1M | $14.5M | |
| Total Liabilities | $37.2M | $24.9M | $26.4M | $23.4M | $21.7M | |
| Total Equity | $105M | $230.6M | $221.4M | $255.5M | $257.3M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$99.2M | -$87.5M | -$8.6M | -$22.9M | -$19.1M | |
| Cash From Investing | $39.7M | -$91.4M | $48.3M | $19M | $4.4M | |
| Cash From Financing | $85M | $118.1M | $3M | -- | $635K | |
| Free Cash Flow | -$101.6M | -$88.1M | -$8.7M | -$23M | -$19.1M | |
FULC
Sector
Market Cap
$199M
$43.4M
Price % of 52-Week High
26.93%
48.26%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.75%
1-Year Price Total Return
-59.41%
-34.26%
Beta (5-Year)
2.034
0.749
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$3.68
200-day SMA
Sell
Level
$5.75
Bollinger Bands (100)
Sell
Level
3.31 - 4.29
Chaikin Money Flow
Sell
Level
-45.8M
20-day SMA
Sell
Level
$3.89
Relative Strength Index (RSI14)
Sell
Level
41.55
ADX Line
Sell
Level
30.42
Williams %R
Neutral
Level
-63.2184
50-day SMA
Sell
Level
$4.16
MACD (12, 26)
Sell
Level
-0.16
25-day Aroon Oscillator
Sell
Level
-88
On Balance Volume
Neutral
Level
214.8M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (8.0332)
Sell
CA Score
(Annual)
Level (-0.7018)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (3)
Sell
Ohlson Score
Level (6.2318)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.
Stock Forecast FAQ
In the current month, FULC has received 1 Buy ratings 4 Hold ratings, and 0 Sell ratings. The FULC average analyst price target in the past 3 months is $5.67.
-
Where Will Fulcrum Therapeutics Stock Be In 1 Year?
According to analysts, the consensus estimate is that Fulcrum Therapeutics share price will rise to $5.67 per share over the next 12 months.
-
What Do Analysts Say About Fulcrum Therapeutics?
Analysts are divided on their view about Fulcrum Therapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Fulcrum Therapeutics is a Sell and believe this share price will drop from its current level to $2.00.
-
What Is Fulcrum Therapeutics's Price Target?
The price target for Fulcrum Therapeutics over the next 1-year time period is forecast to be $5.67 according to 5 Wall Street analysts, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 4 analysts rate the stock a Hold.
-
Is FULC A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Fulcrum Therapeutics is a Hold. 4 of 5 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of FULC?
You can purchase shares of Fulcrum Therapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Fulcrum Therapeutics shares.
-
What Is The Fulcrum Therapeutics Share Price Today?
Fulcrum Therapeutics was last trading at $3.69 per share. This represents the most recent stock quote for Fulcrum Therapeutics. Yesterday, Fulcrum Therapeutics closed at $3.69 per share.
-
How To Buy Fulcrum Therapeutics Stock Online?
In order to purchase Fulcrum Therapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is DoorDash a Buy, Sell or Hold?
Gig economy food delivery service DoorDash (NASDAQ:DASH) has been running…
Is Clorox’s Dividend Worth It?
Clorox (NYSE:CLX) is the parent company of some of the…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 40x
Buy
61
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 116x
Sell
47
Is MSFT Stock a Buy?
Market Cap: $3T
P/E Ratio: 35x
Alerts
Buy
87
PCOR alert for Feb 15
Procore Technologies [PCOR] is up 16.3% over the past day.
Buy
54
DKNG alert for Feb 15
DraftKings [DKNG] is up 15.24% over the past day.
Sell
30
TWLO alert for Feb 15
Twilio [TWLO] is down 15.01% over the past day.
